Article

Glaucoma risk calculator, the need for adherence to medication take center stage in 2005

The landscape of glaucoma has been relatively quiet during 2005, but experts in the field agree there have been a few noteworthy developments.

For a wrap-up of some of the important advances that have occurred in both basic and clinical science, Ophthalmology Times spoke with Robert D. Fechtner, MD, Eve J. Higginbotham, MD, Harry A. Quigley, MD, and Robert N. Weinreb, MD.

Risk calculator debut

"This is the first time a risk calculator for use in managing an ophthalmologic disease has been developed and validated, and our validation confirmed it provides fairly reliable predictions of probability risk," said Dr. Weinreb, distinguished professor of ophthalmology, University of California, San Diego, and director of the university's Hamilton Glaucoma Center.

"With this validated tool, clinicians are now positioned to make individual risk assessments for patients with ocular hypertension just as cardiologists have been doing to predict the 10-year risk of a coronary event using a combination of data on cholesterol, blood pressure, and other factors," said Dr. Fechtner, professor of ophthalmology, and director, glaucoma division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

"This risk assessment analysis has been converted into an easy-to-use slide rule that was introduced at the annual meeting of the American Academy of Ophthalmology, and we can expect risk modeling will play an increasing role in glaucoma therapy in the future," said Dr. Quigley, A. Edward Maumenee Professor of Ophthalmology, and director, Glaucoma Service, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.